Loading
The trial that made relma-cel the first CAR-T developed and manufactured in China to be approved, with three quarters of patients responding.
59 patients treated (Cancer Medicine 2021): objective response 75.9%, complete response 51.7%, with grade 3 or higher cytokine release syndrome in about 5% and neurotoxicity in about 3%, a favourable profile consistent with the 4-1BB construct shared with lisocabtagene maraleucel. Basis of NMPA approval in September 2021.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Relmacabtagene autoleucel, JW Therapeutics and the tag china.
Shares JW Therapeutics and the tag china.
Shares CD19, CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.